



7 January 2008
Australian Securities Exchange

COMPANY ANNOUNCEMENT (ASX:QRX)

QRxPharma Reports Feedback from the FDA on its Clinical Development Plan for Q8003IR

QRxPharma is pleased to report that it has received feedback from the US Food & Drug Administration (FDA) concerning the moderate to severe, acute pain clinical trial program currently in place for Q8003IR.

QRxPharma previously received FDA authorisation to initiate Phase III clinical studies for Q8003IR in chronic pain. To more fully capitalise on the clinical advantages of the compound, QRxPharma recently submitted a request to the FDA to provide feedback on a new development program for Q8003IR focusing on acute pain.

“This specific clinical trial plan feedback we received from the FDA reinforces the direction we have taken and provides us with a positive indication to continue with the overall clinical trial program as planned for the product” said Dr. Warren Stern, Senior VP Drug Development.

Dr. John Holaday, Managing Director and CEO, said: “With the start of two clinical trials at the end of 2007, and this recent FDA feedback, we remain on track with our development plans to bring Q8003IR to market by the second half of 2010”.

Q8003IR is a patent-protected, immediate release combination of morphine and oxycodone that is being developed by QRxPharma for the treatment of moderate to severe, acute pain.

For more information please contact:
Chris J Campbell
Chief Financial Officer and Company Secretary
Tel: +61 2 9242 8021
Email: chris.campbell@qrxpharma.com

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a focused business strategy to expand the clinical utility and commercial value of marketed compounds, the Company’s product portfolio includes both late and early stage clinical drug candidates with the potential for reduced development risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma’s lead compound, Q8003IR, began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: www.QRxPharma.com.